The firm is investigating the proposed sale of Theravance Biopharma (TBPH) to Zymeworks, where shareholders are slated to receive $176.00 per share plus a contingent value right. Simultaneously, scrutiny is directed at Iridium Communications (IRDM) and its agreement to merge with Rocket Lab Corporation, a deal involving $27.00 in cash and a stock exchange ratio. LCI Industries (LCII) is also under review following its planned merger with Patrick Industries (PATK). Under the terms of that agreement, LCI shareholders are set to receive 1.2440 shares of Patrick common stock for each share held, leaving Patrick shareholders with roughly 52% of the combined entity.

Monteverde & Associates operates from the Empire State Building and emphasizes its history of securities litigation, including appearances before the U.S. Supreme Court. The firm is encouraging stakeholders to review the potential impact of these transactions on their investment value. Those holding common stock in these companies can contact Juan Monteverde at (212) 971-1341 or via the firm’s website to discuss their concerns regarding these corporate actions.